Raanana, Israel, July 15, 2025 - Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in intranasal hydrogels, has successfully retained its listing on the Nasdaq Capital Market. Following a hearing on June 26, 2025, the Nasdaq Hearings Panel granted Polyrizon's request to continue its listing, provided the company complies with the Minimum Bid Price Rule by October 17, 2025. The company has committed to avoiding complex or dilutive financing instruments in future capital-raising activities and is implementing an internal control framework to ensure compliance with Nasdaq standards. CEO Tomer Izraeli expressed optimism about enhancing shareholder value and strengthening the company's business position.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。